Prestroke Antiplatelet Effect on Symptomatic Intracranial Hemorrhage and Functional Outcome in Intravenous Thrombolysis

BACKGROUND AND PURPOSE: About 30%-40% of stroke patients are taking antiplatelet at the time of their strokes, which might increase the risk of symptomatic intracranial hemorrhage (SICH) with intravenous tissue plasminogen activator (IV-TPA) therapy. We aimed to assess the effect of prestroke antipl...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Jay Chol, Lee, Ji Sung, Park, Tai Hwan, Cho, Yong-Jin, Park, Jong-Moo, Kang, Kyusik, Lee, Kyung Bok, Lee, Soo Joo, Kim, Jae Guk, Lee, Jun, Park, Man-Seok, Choi, Kang-Ho, Kim, Joon-Tae, Yu, Kyung-Ho, Lee, Byung-Chul, Oh, Mi-Sun, Cha, Jae-Kwan, Kim, Dae-Hyun, Nah, Hyun-Wook, Kim, Dong-Eog, Ryu, Wi-Sun, Kim, Beom Joon, Bae, Hee-Joon, Kim, Wook-Joo, Shin, Dong-Ick, Yeo, Min-Ju, Sohn, Sung Il, Hong, Jeong-Ho, Lee, Juneyoung, Hong, Keun-Sik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Stroke Society 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066428/
https://www.ncbi.nlm.nih.gov/pubmed/27733024
http://dx.doi.org/10.5853/jos.2016.00185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066428/
https://www.ncbi.nlm.nih.gov/pubmed/27733024
http://dx.doi.org/10.5853/jos.2016.00185

Ejemplares similares